Effects of resistance exercise in prostate cancer patients: a meta-analysis

Supportive Care in Cancer

Volumn 25, Issue 9, 2017, Pages 2953-2968

  Keilani, M ^a   Hasenoehrl, T ^a   Baumann, L ^a   Ristl, R ^a   Schwarz, M ^a   Marhold, M ^a   Sedghi Komandj, T ^a   Crevenna, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Androgen deprivation therapy; Body composition; Muscular strength; Physical performance; Prostate cancer; Resistance exercise

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; BODY COMPOSITION; BODY FAT; BODY MASS; CANCER PATIENT; CANCER REHABILITATION; FAT MASS; FATIGUE; FUNCTIONAL ASSESSMENT; HUMAN; LEAN BODY WEIGHT; MALE; META ANALYSIS; MUSCLE MASS; MUSCLE STRENGTH; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANCE TRAINING; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TRUNK; EXERCISE; KINESIOTHERAPY; PHYSIOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; PSYCHOLOGY;

EXERCISE; EXERCISE THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 85020624548     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-017-3771-z     Document Type: Review

References (83)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386. doi:10.1002/ijc.29210
2. Statistik Austria (2016) Prostata (C61) - Relative Überlebensraten in Österreich nach Geschlecht (1987–2014). 2016
3. Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, Drake CG, de Bono JS (2016) Prostate cancer. Lancet 387:70–82. doi:10.1016/S0140-6736(14)61947-4
4. Rhee H, Gunter JH, Heathcote P, Ho K, Stricker P, Corcoran NM, Nelson CC (2015) Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int 115:3–13. doi:10.1111/bju.12964
5. Llorente MD, Burke M, Gregory GR, Bosworth HB, Grambow SC, Horner RD, Golden A, Olsen EJ (2005) Prostate cancer: a significant risk factor for late-life suicide. Am J Geriatr Psychiatry 13:195–201. doi:10.1176/appi.ajgp.13.3.195
6. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson C, Watson RB, Gardiner RA (2002) Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 90:427–432. doi:10.1046/j.1464-410X.2002.02917.x
7. Walker LM, Tran S, Robinson JW (2013) Luteinizing hormone-releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Cancer 11:375–384. doi:10.1016/j.clgc.2013.05.004
8. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson CE, Watson RB, Gardiner RA (2004) Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 93:975–979. doi:10.1111/j.1464-410X.2004.04763.x
9. Cormie P, Oliffe JL, Wootten AC, Galvão DA, Newton RU, Chambers SK (2016) Improving psychosocial health in men with prostate cancer through an intervention that reinforces masculine values—exercise. Psychooncology 25:232–235. doi:10.1002/pon.3867
10. Keating NL, O’Malley AJ, Freedland SJ, Smith MR (2013) Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol 64:159–166. doi:10.1016/j.eururo.2012.04.035
11. Levine GN, D’Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society and the AUA (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121:833–840. doi:10.1161/CIRCULATIONAHA.109.192695
12. Galvão DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R (2008) Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 102:44–47. doi:10.1111/j.1464-410X.2008.07539.x
13. Galvão DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU (2009) Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 12:198–203. doi:10.1038/pcan.2008.51
14. Smith MR, Lee H, Fallon MA, Nathan DM (2008) Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 71:318–322. doi:10.1016/j.urology.2007.08.035
15. Hamilton EJ, Ghasem-Zadeh A, Gianatti E, Lim-Joon D, Bolton D, Zebaze R, Seeman E, Zajac JD, Grossmann M (2010) Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J Clin Endocrinol Metab 95:E456–E463. doi:10.1210/jc.2010-0902
16. Beebe-Dimmer JL, Cetin K, Shahinian V, Morgenstern H, Yee C, Schwartz KL, Acquavella J (2012) Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States. Pharmacoepidemiol Drug Saf 21:70–78. doi:10.1002/pds.2258
17. Storer TW, Miciek R, Travison TG (2012) Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl 14:204–221. doi:10.1038/aja.2011.104
18. Hasenoehrl T, Keilani M, Sedghi Komanadj T, Mickel M, Margreiter M, Marhold M, Crevenna R (2015) The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review. Support Care Cancer 23:2479–2497. doi:10.1007/s00520-015-2782-x
19. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD (2006) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev CD006019. doi: 10.1002/14651858.CD006019.pub2
20. Higano CS (2012) Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer. J Clin Oncol 30:3720–3725. doi:10.1200/JCO.2012.41.8509
21. Harrington JM, Schwenke DC, Epstein DR, Bailey DE (2014) Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer. Oncol Nurs Forum 41:21–29. doi:10.1188/14.ONF.21-29
22. Bolla M, de Reijke TM, Van Tienhoven G, den Bergh ACM V, Oddens J, Poortmans PMP, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L, EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516–2527. doi:10.1056/NEJMoa0810095
23. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU, Radiation Therapy Oncology Group (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21:3972–3978. doi:10.1200/JCO.2003.11.023
24. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D, Carroll PR (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Urol Oncol Semin Orig Investig 23:462–463. doi:10.1016/j.urolonc.2005.08.015
25. Wilke DR, Krahn M, Tomlinson G, Bezjak A, Rutledge R, Warde P (2010) Sex or survival: short-term versus long-term androgen deprivation in patients with locally advanced prostate cancer treated with radiotherapy. Cancer 116:1909–1917. doi:10.1002/cncr.24905
26. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S (2006) Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 18:494–498. doi:10.1038/sj.ijir.3901471
27. Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU (2009) Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure. Prostate Cancer Prostatic Dis 12:233–240. doi:10.1038/pcan.2009.12
28. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C (2003) Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 104:195–201. doi:10.1042/CS20020209
29. Collier A, Ghosh S, McGlynn B, Hollins G (2012) Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease. Am J Clin Oncol 35:504–509. doi:10.1097/COC.0b013e318201a406
30. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS (2007) Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110:1493–1500. doi:10.1002/cncr.22933
31. Nguyen PL, Chen M-H, Beckman JA, Beard CJ, Martin NE, Choueiri TK, Hu JC, Hoffman KE, Dosoretz DE, Moran BJ, Salenius SA, Braccioforte MH, Kantoff PW, D’Amico AV, Ennis RD (2012) Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys 82:1411–1416. doi:10.1016/j.ijrobp.2011.04.067
32. Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164. doi:10.1056/NEJMoa041943
33. D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420–2425. doi:10.1200/JCO.2006.09.3369
34. Strasser B, Steindorf K, Wiskemann J, Ulrich CM (2013) Impact of resistance training in cancer survivors: a meta-analysis. Med Sci Sports Exerc 45:2080–2090. doi:10.1249/MSS.0b013e31829a3b63
35. Lemes IR, Ferreira PH, Linares SN, Machado AF, Pastre CM, Netto JJ (2016) Resistance training reduces systolic blood pressure in metabolic syndrome: a systematic review and meta-analysis of randomised controlled trials. Br J Sports Med 50:1–6. doi:10.1136/bjsports-2015-094715
36. Ricci-Vitor AL, Bonfim R, Fosco LC, Bertolini GN, Ramos EMC, Ramos D, Pastre CM, Godoy M, Vanderlei LCM (2013) Influence of the resistance training on heart rate variability, functional capacity and muscle strength in the chronic obstructive pulmonary disease. Eur J Phys Rehabil Med 49:793–801
37. Smith MR (2003) Changes in body composition during hormonal therapy for prostate cancer. Clin Prostate Cancer 2:18–21
38. Strasser B, Arvandi M, Siebert U (2012) Resistance training, visceral obesity and inflammatory response: a review of the evidence. Obes Rev 13:578–591. doi:10.1111/j.1467-789X.2012.00988.x
39. Bourke L, Doll H, Crank H, Daley A, Rosario D, Saxton JM (2011) Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study. Cancer Epidemiol Biomark Prev 20:647–657. doi:10.1158/1055-9965.EPI-10-1143
40. Bourke L, Gilbert S, Hooper R, Steed LA, Joshi M, Catto JWF, Saxton JM, Rosario DJ (2014) Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 65:865–872. doi:10.1016/j.eururo.2013.09.040
41. Cormie P, Newton RU, Spry N, Joseph D, Taaffe DR, Galvão DA (2013) Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis 16:328–335. doi:10.1038/pcan.2013.22
42. Cormie P, Galvão DA, Spry N, Joseph D, Chee R, Taaffe DR, Chambers SK, Newton RU (2015) Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int 115:256–266. doi:10.1111/bju.12646
43. Galvão DA, Nosaka K, Taffee DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Yamaya K, Newton RU (2006) Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 38:2045–2052. doi:10.1249/01.mss.0000233803.48691.8b
44. Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28:340–347. doi:10.1200/JCO.2009.23.2488
45. Galvão DA, Spry N, Denham J, Taaffe DR, Cormie P, Joseph D, Lamb DS, Chambers SK, Newton RU (2014) A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 radar. Eur Urol 65:856–864. doi:10.1016/j.eururo.2013.09.041
46. Hanson ED, Sheaff AK, Sood S, Ma L, Francis JD, Goldberg AP, Hurley BF (2013) Strength training induces muscle hypertrophy and functional gains in black prostate cancer patients despite androgen deprivation therapy. J Gerontol Ser A Biol Sci Med Sci 68:490–498. doi:10.1093/gerona/gls206
47. Mina DS, Alibhai SMH, Matthew AG, Guglietti CL, Pirbaglou M, Trachtenberg J, Ritvo P (2013) A randomized trial of aerobic versus resistance exercise in prostate cancer survivors. J Aging Phys Act 21:455–478
48. Park SW, Kim TN, Nam JK, Ha HK, Shin DG, Lee W, Kim MS, Chung MK (2012) Recovery of overall exercise ability, quality of life, and continence after 12-week combined exercise intervention in elderly patients who underwent radical prostatectomy: a randomized controlled study. Urology 80:299–305. doi:10.1016/j.urology.2011.12.060
49. Segal RJ (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21:1653–1659. doi:10.1200/JCO.2003.09.534
50. Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud’Homme DG, Malone SC, Wells GA, Scott CG, Slovinec D’Angelo ME (2009) Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 27:344–351. doi:10.1200/JCO.2007.15.4963
51. Winters-Stone MK, Dobek CJ, Bennett AJ, Maddalozzo FG, Ryan WC, Beer MT (2014) Skeletal response to resistance and impact training in prostate cancer survivors. Med Sci Sports Exerc 46:1482–1488. doi:10.1249/MSS.0000000000000265
52. Livingston PM, Craike MJ, Salmon J, Courneya KS, Gaskin CJ, Fraser SF, Mohebbi M, Broadbent S, Botti M, Kent B (2015) Effects of a clinician referral and exercise program for men who have completed active treatment for prostate cancer: a multicenter cluster randomized controlled trial (ENGAGE). Cancer 121:2646–2654. doi:10.1002/cncr.29385
53. Nilsen TS, Raastad T, Skovlund E, Courneya KS, Langberg CW, Lilleby W, Fosså SD, Thorsen L (2015) Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy. Acta Oncol (Madr) 54:1805–1813. doi:10.3109/0284186X.2015.1037008
54. Winters-Stone KM, Lyons KS, Dobek J, Dieckmann NF, Bennett JA, Nail L, Beer TM (2016) Benefits of partnered strength training for prostate cancer survivors and spouses: results from a randomized controlled trial of the Exercising Together project. J Cancer Surviv 10:633–644 1–12. doi:10.1007/s11764-015-0509-0
55. Hojan K, Kwiatkowska-Borowczyk E, Leporowska E, Gorecki M, Ozga-Majchrzak O, Milecki TMP (2016) Physical exercise for functional capacity, blood immune function, fatigue and quality of life in high-risk prostate cancer patients during radiotherapy. A prospective, randomised clinical study. Eur J Phys Rehabil Med 52:489–501
56. Alberga AS, Segal RJ, Reid RD, Scott CG, Sigal RJ, Khandwala F, Jaffey J, Wells GA, Kenny GP (2012) Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer. Support Care Cancer 20:971–981. doi:10.1007/s00520-011-1169-x
57. Buffart LM, Galvão DA, Chinapaw MJ, Brug J, Taaffe DR, Spry N, Joseph D, Newton RU (2014) Mediators of the resistance and aerobic exercise intervention effect on physical and general health in men undergoing androgen deprivation therapy for prostate cancer. Cancer 120:294–301. doi:10.1002/cncr.28396
58. Cormie P, Newton RU, Taaffe DR, Spry N, Joseph D, Akhlil Hamid M, Galvão DA (2013) Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: a randomized controlled trial. Prostate Cancer Prostatic Dis 16:170–175. doi:10.1038/pcan.2012.52
59. Courneya KS, Segal RJ, Reid RD, Jones LW, Malone SC, Venner PM, Parliament MB, Scott CG, Quinney HA, Wells GA (2004) Three independent factors predicted adherence in a randomized controlled trial of resistance exercise training among prostate cancer survivors. J Clin Epidemiol 57:571–579. doi:10.1016/j.jclinepi.2003.11.010
60. Galvão DA, Nosaka K, Taaffe DR, Peake J, Spry N, Suzuki K, Yamaya K, McGuigan MR, Kristjanson LJ, Newton RU (2008) Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer Prostatic Dis 11:160–165. doi:10.1038/sj.pcan.4500991
61. Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU (2011) Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response. J Urol 186:1291–1297. doi:10.1016/j.juro.2011.05.055
62. Mina DS, Connor MK, Alibhai SMH, Toren P, Guglietti C, Matthew AG, Trachtenberg J, Ritvo P (2013) Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: a randomized study. Can Urol Assoc J 7:E692–E698. doi:10.5489/cuaj.235
63. Winters-Stone KM, Dobek JC, Bennett JA, Dieckmann NF, Maddalozzo GF, Ryan CW, Beer TM (2014) Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial. Arch Phys Med Rehabil 96:7–14. doi:10.1016/j.apmr.2014.08.010
64. Gaskin CJ, Fraser SF, Owen PJ, Craike M, Orellana L, Livingston PM (2016) Fitness outcomes from a randomised controlled trial of exercise training for men with prostate cancer: the ENGAGE study. J Cancer Surviv. doi:10.1007/s11764-016-0543-6
65. Nilsen TS, Thorsen L, Fosså SD, Wiig M, Kirkegaard C, Skovlund E, Benestad HB, Raastad T (2015) Effects of strength training on muscle cellular outcomes in prostate cancer patients on androgen deprivation therapy. Scand J Med Sci Sports 26:1026–1035. doi:10.1111/sms.12543
66. Nilsen TS, Thorsen L, Kirkegaard C, Ugelstad I, Fosså SD, Raastad T (2016) The effect of strength training on muscle cellular stress in prostate cancer patients on ADT. Endocr Connect 5:74–82. doi:10.1530/EC-15-0120
67. Buffart LM, Newton RU, Chinapaw MJ, Taaffe DR, Spry NA, Denham JW, Joseph DJ, Lamb DS, Brug J, Galvao DA (2015) The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer. Cancer 121:2821–2830. doi:10.1002/cncr.29406
68. Gilbert SE, Tew GA, Fairhurst C, Bourke L, Saxton JM, Winter EM, Rosario DJ (2016) Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer. Br J Cancer 114:401–408. doi:10.1038/bjc.2015.479
69. Lyons KS, Winters-Stone KM, Bennett JA, Beer TM (2016) The effects of partnered exercise on physical intimacy in couples coping with prostate cancer. Health Psychol 35:509–513. doi:10.1037/hea0000287
70. Winters-Stone KM, Dieckmann N, Maddalozzo GF, Bennett JA, Ryan CW, Beer TM (2015) Resistance exercise reduces body fat and insulin during androgen-deprivation therapy for prostate cancer. Oncol Nurs Forum 42:348–356. doi:10.1188/15.ONF.348-356
71. Gonnermann A, Framke T, Großhennig A, Koch A (2015) No solution yet for combining two independent studies in the presence of heterogeneity. Stat Med 34:2476–2480. doi:10.1002/sim.6473
72. Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36:1–48. doi:10.1103/PhysRevB.91.121108
73. Cormie P, Pumpa K, Galvão DA, Turner E, Spry N, Saunders C, Zissiadis Y, Newton RU (2013) Is it safe and efficacious for women with lymphedema secondary to breast cancer to lift heavy weights during exercise: a randomised controlled trial. J Cancer Surviv 7:413–424. doi:10.1007/s11764-013-0284-8
74. Muehlbauer T, Besemer C, Wehrle A, Gollhofer A, Granacher U (2012) Relationship between strength, power and balance performance in seniors. Gerontology 58:504–512. doi:10.1159/000341614
75. Beauchamp MK, Jette AM, Ward RE, Kurlinski LA, Kiely D, Latham NK, Bean JF (2015) Predictive validity and responsiveness of patient-reported and performance-based measures of function in the Boston RISE Study. J Gerontol Ser A Biol Sci Med Sci 70:616–622. doi:10.1093/gerona/glu227
76. Kwon S, Perera S, Pahor M, Katula JA, King AC, Groessl EJ, Studenski SA (2009) What is a meaningful change in physical performance? Findings from a clinical trial in older adults (The LIFE-P study). J Nutr Heal Aging 13:538–544. doi:10.1007/s12603-009-0104-z
77. Chipperfield K, Fletcher J, Millar J, Brooker J, Smith R, Frydenberg M, Burney S (2013) Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy. Psychooncology 22:2169–2176. doi:10.1002/pon.3269
78. Gardner JR, Livingston PM, Fraser SF (2014) Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol 32:335–346. doi:10.1200/JCO.2013.49.5523
79. Weaver KE, Forsythe LP, Reeve BB, Alfano CM, Rodriguez JL, Sabatino SA, Hawkins NA, Rowland JH (2012) Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomark Prev 21:2108–2117. doi:10.1158/1055-9965.EPI-12-0740
80. Silver J, Baima J, Mayer R (2013) Impairment-driven cancer rehabilitation. Cancer J Clin 63:295–317. doi:10.3322/caac.21186
81. Hasenoehrl T, Wessner B, Tschan H, Vidotto C, Crevenna R, Csapo R (2016) Eccentric resistance training intensity may affect the severity of exercise induced muscle damage. J Sports Med Phys Fitness
82. Ahmadi H, Daneshmand S (2013) Androgen deprivation therapy: evidence-based management of side effects. BJU Int 111:543–548. doi:10.1111/j.1464-410X.2012.11774.x
83. Alibhai SMH, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, Krahn M, Fleshner NE, Warde P, Canning SD, Klotz L, Naglie G (2010) Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol 28:5038–5045. doi:10.1200/JCO.2010.29.8091